All In Biotech

Free tool

FAERS Monitor: Cefoxitin and Dextrose In Duplex Container

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 065214 or its brand name (Cefoxitin and Dextrose In Duplex Container, Cefoxitin Sodium). Reports on generic versions are filed under their own applications.

Reports

204

Serious

177

87% of reports

Hospitalization

73

Death reported

21

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use19
  • rash13
  • drug hypersensitivity12
  • anaphylactic shock11
  • nausea11
  • pneumonia11
  • thrombocytopenia11
  • diarrhoea10
  • acute kidney injury9
  • leukopenia9
  • platelet count decreased9
  • pyrexia9
  • urinary tract infection9
  • dyspnoea8
  • pruritus8

Reports by year received

View as table
YearReports
20043
20071
20082
20091
20101
20111
20125
20133
20145
20156
201618
201715
201822
201922
20208
202112
202211
202322
202428
20258
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,955 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaphylactic shockSignal1144.024.8421
leukopeniaSignal918.69.8133
thrombocytopeniaSignal1110.15.782
platelet count decreasedSignal98.74.654
drug hypersensitivitySignal126.43.750
acute kidney injurySignal96.13.233
urinary tract infectionSignal95.42.929
pneumoniaSignal113.52.018
rashSignal133.11.817
pyrexiaSignal92.71.48
off label useSignal192.21.512
pruritus82.11.14
diarrhoea101.60.92
dyspnoea81.50.71
nausea111.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.